The EXACT Trial (NCT04125732)
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment
This is a Phase 1/2, first-in-human, multicenter, open-label, single-arm dose-escalation trial of XC001. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 32 additional subjects. XC001 will be administered by a transthoracic epicardial procedure. Safety will be the focus for the initial 6 months after XC001 administration followed by one safety-focused telephone evaluation at Month 12.
PI: Dr. Emerson Perin, MD, PhD
SPONSOR: XyloCor Therapeutics, Inc.